Trial · NCT06686030
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
NCT06686030, Phase 2, Recruiting, Akeso
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer. Trials, record NCT06686030. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06686030
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
- NCT number
- NCT06686030
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Akeso
- Conditions
- Platinum-sensitive Ovarian Cancer
- Interventions
- AK112 low dose, Chemotherapy, Olaparib, AK112 high dose
- First posted
- 2024-11-13
- Last updated
- 2025-04-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) assessed by investigator per RECIST v1.1 | up to 2 years | PFS is defined as the time from the date of first dosing till the first documented disease progression Per RECIST v1.1 assessed by the investigator or death due to any cause, whichever occurs first. |
| Secondary | Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by investigator | Up to 2 years | Proportion of subjects who have a complete or partial response relative to baseline as assessed by investigator according to RECIST 1.1 criteria |
| Secondary | Disease control rate(DCR)assessed by investigator per RECIST v1.1 | Up to 2 years | Proportion of subjects who have received response(ie complete response or partial response) or stable disease relative to baseline as assessed by investigator according to RECIST 1.1 criteria |
| Secondary | Duration of Response (DOR) assessed by investigator per RECIST v1.1 | Up to 2 years | DOR means time measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria. |
| Secondary | Time to Response (TTR) assessed by investigator per RECIST v1.1 | Up to 2 years | TTR refers to Time to Response. |
| Secondary | Overall Survival(OS) | Up to 2 years | OS is defined as the time from randomization or first dosing to death due to any cause. |
| Secondary | Number of participants with adverse event (AE) | Up to 2 years | The number of participants experiencing an AE and the severity of AEs will be assessed. AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06686030
GET https://conductscience.org/api/trials/v1/NCT06686030/registered